Phathom Pharmaceuticals Inc
$ 9.82
-1.80%
09 Jun - close price
- Market Cap 807,928,000 USD
- Current Price $ 9.82
- High / Low $ 10.23 / 9.79
- Stock P/E N/A
- Book Value -4.24
- EPS -2.09
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -34.89 %
- 52 Week High 18.31
- 52 Week Low 7.61
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Analyst Target Price
$23.70
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-10-30 | 2025-08-07 | 2025-05-01 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.18 | -0.29 | -0.15 | -0.79 | -1.07 | -1.05 | -1.05 | -1.25 | -1.11 | -1.39 | -0.76 | -0.84 |
| Estimated EPS | -0.3897 | -0.38 | -0.41 | -0.92 | -1.066 | -1.08 | -1.46 | -1.24 | -1.22 | -1.08 | -0.96 | -0.95 |
| Surprise | 0.2097 | 0.09 | 0.26 | 0.13 | -0.004 | 0.03 | 0.41 | -0.01 | 0.11 | -0.31 | 0.2 | 0.11 |
| Surprise Percentage | 53.8106% | 23.6842% | 63.4146% | 14.1304% | -0.3752% | 2.7778% | 28.0822% | -0.8065% | 9.0164% | -28.7037% | 20.8333% | 11.5789% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAT
2026-05-28 20:40:11
Phathom Pharmaceuticals currently exhibits a negative Return on Invested Capital (ROIC) of -53.45%, significantly below its Weighted Average Cost of Capital (WACC) of 15.49%, indicating it is destroying shareholder value. This is typical for clinical-stage biopharmaceutical companies due to substantial research and development expenses before commercialization. Compared to its peers, only Arcutis Biotherapeutics shows a positive ROIC, albeit still below its WACC, suggesting better, yet still insufficient, capital efficiency.
2026-05-27 20:10:17
Phathom Pharmaceuticals director Asit Parikh reported gifting 56,000 shares of common stock on May 22, 2026. These transfers were bona fide gifts to a trust benefiting his spouse and were not market trades. The transactions reflect estate or family planning rather than buying or selling activity, with no consideration received.
2026-05-26 04:34:00
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) using AI models, highlighting weak near-term sentiment but potential long-term strength. It outlines various trading strategies—position, momentum, and risk hedging—and provides multi-timeframe signal analysis with specific support and resistance levels. The analysis aims to inform risk allocation models by detailing entry/exit points, targets, and stop-loss levels for different risk profiles.
2026-05-24 13:09:26
This page provides a comprehensive overview of Phathom Pharmaceuticals (PHAT) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event disclosures. It details recent insider transactions, changes in beneficial ownership by various investment groups like Carlyle and Millennium, and significant executive compensation awards. The resource aims to offer investors and traders access to critical regulatory documents and AI-generated analyses of these filings.
2026-05-22 23:40:25
Phathom Pharmaceuticals, Inc. announced that its management team will attend three upcoming investor conferences in May and June: the Craig-Hallum 23rd Annual Institutional Investor Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management will participate in one-on-one meetings at each event, with fireside chats scheduled for the Jefferies and Goldman Sachs conferences. Investors can access live webcasts and archived recordings on the company's website.
2026-05-22 12:10:41
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in three investor conferences in May and June 2026: the Craig-Hallum Institutional Investor Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference. Management will attend these events to participate in one-on-one meetings and fireside chats. The company, focused on GI treatments, will discuss vonoprazan, its first-in-class potassium-competitive acid blocker.
